|
|
|
|
|
|
|
|
|
|
For your convenience the TRELSTAR Support Line is available. For comprehensive support
services, including information on ordering TRELSTAR, reimbursement, Indigent Patient
Program, drug safety and adverse event reporting and medical and general nonmedical
information.
Call
866-755-3315
|
|
|
|
Reimbursement counselors are available from 9:00 AM to 8:00 PM EST to help
you with the following services:
Insurance coverage verification
- Contacting insurers to determine each patient’s insurance coverage, co-payment
obligations, and availability of benefits.
- Providing information and general assistance regarding insurers’ pre-certification
and prior-authorization procedures.
Coding and coverage
- Confirming proper coding to use on claim forms.
- Providing guidance and updated information regarding payer policies for physicians,
reimbursement managers, and other office staff.
Claim review and denial assistance
- Reviewing denied claims for accuracy and completeness.
- Obtaining appropriate reimbursement by assisting in the denial and appeals process.
- Preparing a letter of medical necessity.
- Communicating with your office to ensure that appealed claims are reimbursed appropriately.
Indigent Patient Program
- Screening patients for eligibility and enrolling indigent patients who need assistance
obtaining TRELSTAR.
- Identifying alternate funding sources for patients who are uninsured or underinsured.
|
|
|
|
Side effect/adverse events reporting
- Allows you to report side effects or adverse events related to TRELSTAR or other
Watson products.
Medical information
- Professionals from Watson’s Medical Communications Department will answer
your medical questions about TRELSTAR or other Watson products.
Quality control and assurance
- Allows you to report a product quality-related complaint regarding TRELSTAR or
other Watson products.
|
|
|
|
Obtain answers to your general questions about TRELSTAR
Watson Pharma is committed to providing your office with ample
reimbursement support services and is pleased to provide you with the 2008 TRELSTAR
Reimbursement Guide. The purpose of this guide is to assist physicians and medical
billing staff with billing and reimbursement for TRELSTAR and to provide guidance
in filing a claim for TRELSTAR therapy.
This guide is provided to you for informational purposes only. For current or additional
information regarding billing and reimbursement, please call the TRELSTAR Support
Line at
866-755-3315
.
Click here to download a PDF file of the guide
To help uninsured patients who require medical intervention with
TRELSTAR, Watson has designed the TRELSTAR Indigent Patient Program. Through this
program, TRELSTAR is provided free of charge to low-income patients who are uninsured
and meet financial eligibility requirements. If you have a patient who may be eligible
for this program:
- Call the TRELSTAR Support Line and explain your patient’s situation to the
Support Line counselor, who may be able to suggest other sources of coverage
- If there is no other source of payment available, the Support Line consultant will
send you a qualification form that requests insurance status and income information.
Patient eligibility must be demonstrated. The form must be completed, signed, and
returned to the TRELSTAR Support Line representative with a prescription for the
patient’s course of TRELSTAR therapy. Additionally, an authorization to disclose
information about the patient in the Indigent Patient Program will also need to
be completed
- A Support Line consultant will review your patient’s eligibility status.
You will be notified by telephone or fax of the patient’s eligibility status
- As soon as it has been determined that a patient is qualified to receive TRELSTAR
free of charge, Watson will provide the medication as prescribed by the physician.
The product will be sent to the physician’s office to be administered to the
patient
- Watson reserves the right to modify or discontinue the TRELSTAR Indigent Patient
Program at any time
|
|
|
|
|
|
|
Indications and Usage
TRELSTAR® Depot and TRELSTAR® LA are indicated in
the palliative treatment of advanced prostate cancer. TRELSTAR Depot and TRELSTAR
LA offer an alternative treatment for prostate cancer when orchiectomy or estrogen
administration are either not indicated or unacceptable to the patient.
|
|
|
|
Safety Information
|
|
The most commonly reported adverse events associated with the use of TRELSTAR Depot/TRELSTAR
LA included hot flushes (58.6%/73.0%), skeletal pain (12.1%/13.2%), impotence (7.1%/2.3%),
headache (5.0%/6.9%), leg pain (2.1%/5.2%), and edema in legs (0.0%/6.3%) . TRELSTAR
is contraindicated in women who are or may become pregnant as well as patients who
are hypersensitive to triptorelin, other LHRH agonists, or LHRH . Infrequent postmarketing
reports of anaphylactic shock and angioedema have been received since 1986 (global
experience) . As with all LHRH agonists, triptorelin causes an initial transient
increase in testosterone levels. Patients may experience the onset or exacerbation
of symptoms during this period, including bone pain, neuropathy, hematuria, spinal
cord compression, or urethral or bladder outlet obstruction. Patients with metastatic
vertebral lesions and/or urinary tract obstruction should be closely observed.
|
|
|
|
|
|
|
|
|
|
